MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
India's Third Giant Leap
This Could be One of the Biggest Opportunities for Investors
- Home
- Todays Market
- Indian Stock Market News November 17, 2016
Sensex Closes in Red for the Fourth Consecutive Session; IT Stocks Hit the Most Thu, 17 Nov Closing
The Indian share markets witnessed some selling pressure during the afternoon session and finished below the dotted line for the fourth consecutive day. At the closing bell, the BSE Sensex closed lower by 71 points, whereas the NSE Nifty finished down by 32 points. The <>S&P BSE Midcap & the S&P BSE Small Cap finished down by 0.4% and 0.6% respectively. IT and capital goods stocks were under pressure. While metal and power stocks led the pack of gainers.
Asian markets finished mixed as of the most recent closing prices. The Shanghai Composite gained 0.11%, while Hong Kong's Hang Seng was off 0.08%. Shares in Japan were unchanged with the Nikkei 225 at 17862.63. European markets are mixed today. The FTSE 100 is up 0.25% while the CAC 40 gains 0.05%. The DAX is off 0.35%.
The rupee was trading at Rs 67.91 against the US$ in the afternoon session. Oil prices were trading at US$ 45.73 at the time of writing.
Lupin's US subsidiary, Gavis Pharmaceuticals LLC, was issued a nod for the Tablets USP, 5mg/300 mg, 7.5 mg/300 mg & 10 mg/300 mg from the United States Food and Drug Administration (USFDA). The Tablets are the AA rated generic equivalent of Mikart, Inc's Hydrocodone Bitartrate and Acetaminophen Tablets.
According to IMS health sales data September 2016, Hydrocodone Bitartrate and Acetaminophen Tablets USP had US sales of US$ 89.6 million.
Meanwhile, Lupin has also launched Amabelz tablets in the American market after getting approval from the USFDA. The tablets are used in prevention of postmenopausal osteoporosis which is a generic version of Amneal Pharmaceuticals' Activella tablets in the US. According to IMS MAT sales data, Activella had US sales of US$91.1 million.
Considering the pharma's regulatory distresses, are Indian pharma companies now adapting to the scrutiny by the USFDA? Bhavita Nagrani, our pharma sector analyst, shares her insights in one of our premium editions of The 5 Minute Wrap Up (Subscription required).
Moving on to the news from stocks in FMCG sector, As per an article in Business Standard, ITC's US-based arm King Maker Marketing Inc. (KMM) has ceased to be its subsidiary. KMM was into business of importing and distributing tobacco products to licensed wholesalers and retailers throughout the USA.
The company had informed earlier that it will be divesting 100% of its equity stake in KMM for an estimated consideration of US$24 million.
Notably, ITC was KMM's sole supplier of tobacco products. The subsidiary recorded net sales of US$ 32.7 million and earned a net income of US$ 0.53 million during the financial year ended 31 March 2016.
The move comes as the cigarette industry in the USA continues to be adversely impacted by long-term decline in cigarette consumption. Further, mislabeled cigarette tobaccos positioned in a lower tax bracket, non-compliant imports and Native American manufacture were also some of the issues. Increasing governmental restrictions and tobacco tax increases were further expected to impact industry growth (Subscription Required) with the threat of shift in consumer franchise to illicit, value offers, the company stated.
HYPERLINK "https://www.equitymaster.com/result.asp?symbol=ITC&name=ITC-LTD-Stock-Quote-Chart" ITC's share price finished the day up by 0.7%.
For information on how to pick stocks that have the potential to deliver big returns, download our special report now!
Read the latest Market Commentary
Indian Share Market Update: Top Gainers and Losers
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
Equitymaster requests your view! Post a comment on "Sensex Closes in Red for the Fourth Consecutive Session; IT Stocks Hit the Most". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!